Antineoplastic agent: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
John Leach (talk | contribs) (removed dubious additions) |
||
| (14 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]], '''antineoplastic agents''' are "substances that inhibit or prevent the proliferation of neoplasms".<ref>{{MeSH}}</ref> Generally, antineoplastic agents are for treating malignant neoplasms such as [[cancer]]s and [[sarcoma]]s. | {{TOC|right}} | ||
In [[medicine]], '''antineoplastic agents''' are "substances that inhibit or prevent the proliferation of neoplasms", otherwise known as cancers.<ref>{{MeSH}}</ref> Generally, antineoplastic agents are for treating malignant neoplasms such as [[cancer]]s and [[sarcoma]]s. | |||
==Classification== | ==Classification== | ||
| Line 9: | Line 10: | ||
==== Nitrogen mustard analogues==== | ==== Nitrogen mustard analogues==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01AA L01AA]. | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01AA L01AA]. Examples include [[cyclophosphamide]], [[chlorambucil]], [[melphalan]]. | ||
==== Alkyl sulfonates==== | ==== Alkyl sulfonates==== | ||
| Line 30: | Line 31: | ||
==== Folic acid analogues==== | ==== Folic acid analogues==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01BA L01BA]. | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01BA L01BA]. Examples include: | ||
* [[Methotrexate]] "is an inhibitor of [[tetrahydrofolate dehydrogenase]] and prevents the formation of [[tetrahydrofolate]], necessary for synthesis of thymidylate, an essential component of DNA."<ref>{{MeSH|Methotrexate}}</ref> | |||
* [[Raltitrexed]] | |||
* [[Pemetrexed]] | |||
==== Purine analogues==== | ==== Purine analogues==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01BB L01BB]. | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01BB L01BB]. Examples include: | ||
* [[mercaptopurine]] is an "antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for [[leukemia]]."<ref>{{MeSH|Mercaptopurine}}</ref> | |||
* [[tioguanine]] | |||
* [[cladribine]] | |||
* [[fludarabine]] | |||
* [[clofarabine]] | |||
* [[nelarabine]] | |||
==== Pyrimidine analogues==== | ==== Pyrimidine analogues==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01BC L01BC]. | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01BC L01BC]. Examples include: | ||
* [[cytarabine]] is a "pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic [[leukemia]]. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties."<ref>{{MeSH|cytarabine}}</ref> | |||
* [[fluorouracil]] | |||
* [[tegafur]] | |||
* [[carmofur]] | |||
* [[gemcitabine]] | |||
* [[capecitabine]] | |||
* [[azacitidine]] | |||
* [[decitabine]] | |||
=== Plant alkaloids and other natural products=== | === Plant alkaloids and other natural products=== | ||
| Line 45: | Line 63: | ||
==== Podophyllotoxin derivatives==== | ==== Podophyllotoxin derivatives==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01CB L01CB]. | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01CB L01CB]. Examples include [[etoposide]]. | ||
==== Colchicine derivatives==== | ==== Colchicine derivatives==== | ||
| Line 72: | Line 90: | ||
==== Platinum compounds==== | ==== Platinum compounds==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XA L01XA]. | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XA L01XA] examples include [[cisplatin]], [[carboplatin]], [[oxaliplatin]], and [[satraplatin]]. | ||
==== Methylhydrazines==== | ==== Methylhydrazines==== | ||
| Line 79: | Line 97: | ||
==== Monoclonal antibodies==== | ==== Monoclonal antibodies==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XC L01XC]. Examples include: | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XC L01XC]. Examples include: | ||
;Anti-EpCAM | ;Anti-EpCAM | ||
* [[Edrecolomab]] is monclonal antibody against EpCAM | * [[Edrecolomab]] is monclonal antibody against EpCAM ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 Entrez protein]). Edrecolomab is a "anticolorectal carcinoma antibody for treatment of advanced [[colorectal cancer|colorectal carcinoma]]".<ref>{{MeSH|edrecolomab [Substance Name]}}</ref> | ||
;Anti- | ;Anti-ErbB1 | ||
* [[ | * [[Cetuximab]] (IMC-C225) is a recombinant, human/mouse chimeric [[monoclonal antibody]] that binds to [[epidermal growth factor receptor]] (ErbB1, EGFR) and may treat head and neck cancers, [[colorectal cancer]], and non-small cell [[lung cancer]] in patients who do not have mutations in the KRAS gene.<ref name="pmid19339720">{{cite journal| author=Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al.| title=Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 14 | pages= 1408-17 | pmid=19339720 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19339720 | doi=10.1056/NEJMoa0805019 }} </ref> | |||
* [[Panitumumab]] is an "antibody that blocks receptors for [[epidermal growth factor receptor]]; approved for advanced [[colorectal cancer|colon cancer]]".<ref>{{MeSH|Panitumumab [Substance Name]}}</ref> | |||
;Anti-ErbB2 | |||
* [[Trastuzumab]] is a "an antibody against the [[ErbB-2 receptor]] that lengthens remission time in metastatic [[breast cancer]]."<ref>{{MeSH|Trastuzumab [Substance Name]}}</ref> | |||
;Anti-CD3 and anti-EpCAM | ;Anti-CD3 and anti-EpCAM | ||
* [[Catumaxomab]]. Is a monoclonal antibody against CD3 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NM_000732 Entrez protein])and EpCAM ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_002345 Entrez protein]). "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".<ref>{{MeSH|Catumaxomab [Substance Name]}}</ref> | |||
; Anti-MS4A1 (CD20 antigen) | ;Anti-MS4A1 (CD20 antigen) | ||
* [[Rituximab]] is a "genetically engineered anti-CD20 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 Entrez protein]) antibody for the treatment of B-cell lymphoma".<ref>{{MeSH|Rituximab [Substance Name]}}</ref> | * [[Rituximab]] is a "genetically engineered anti-CD20 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 Entrez protein]) antibody for the treatment of B-cell lymphoma".<ref>{{MeSH|Rituximab [Substance Name]}}</ref> | ||
| Line 101: | Line 123: | ||
;Anti-VEGF | ;Anti-VEGF | ||
* [[Bevacizumab]] is an "anti-VEGF ( | * [[Bevacizumab]] is an "anti-VEGF ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 Entrez protein]) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref> | ||
[http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_001020537 Entrez protein]) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Bevacizumab [Substance Name]}}</ref> | |||
==== Sensitizers used in photodynamic/radiation therapy==== | ==== Sensitizers used in photodynamic/radiation therapy==== | ||
| Line 108: | Line 129: | ||
==== Protein kinase inhibitors==== | ==== Protein kinase inhibitors==== | ||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XE L01XE]. Examples include [[ | ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XE L01XE]. Examples include [[imatinib]], [[gefitinib]], [[erlotinib]], [[sunitinib]], [[sorafenib]], [[dasatinib]], [[lapatinib]], [[nilotinib]], and [[temsirolimus]]. | ||
==== Other antineoplastic agents==== | |||
ATC/DDD group [http://www.whocc.no/atcddd/indexdatabase/index.php?query=L01XX L01XX]. Examples include [[hydroxycarbamide]] (hydroxyurea), [[tretinoin]], and [[celecoxib]]. | |||
==Dosing== | |||
Dosage may be by the area under the curve (AUC), expressed at mg/mL * min. | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Reviewed Passed]] | |||
Latest revision as of 06:07, 5 April 2024
In medicine, antineoplastic agents are "substances that inhibit or prevent the proliferation of neoplasms", otherwise known as cancers.[1] Generally, antineoplastic agents are for treating malignant neoplasms such as cancers and sarcomas.
Classification
This classification is based on World Health Organization's Collaborating Centre for Drug Statistics Methodology.[2]
Alkylating agents
ATC/DDD group L01A. Alkylating antineoplastic agents are a "class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood."[3]
Nitrogen mustard analogues
ATC/DDD group L01AA. Examples include cyclophosphamide, chlorambucil, melphalan.
Alkyl sulfonates
ATC/DDD group L01AB.
Ethylene imines
ATC/DDD group L01AC.
Nitrosoureas
ATC/DDD group L01AD.
Epoxides
ATC/DDD group L01AG.
Other alkylating agents
ATC/DDD group L01AX.
Antimetabolites
ATC/DDD group L01B. Antineoplastic antimetabolites are "antimetabolites that are useful in cancer chemotherapy."[4]
Folic acid analogues
ATC/DDD group L01BA. Examples include:
- Methotrexate "is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA."[5]
- Raltitrexed
- Pemetrexed
Purine analogues
ATC/DDD group L01BB. Examples include:
- mercaptopurine is an "antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia."[6]
- tioguanine
- cladribine
- fludarabine
- clofarabine
- nelarabine
Pyrimidine analogues
ATC/DDD group L01BC. Examples include:
- cytarabine is a "pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties."[7]
- fluorouracil
- tegafur
- carmofur
- gemcitabine
- capecitabine
- azacitidine
- decitabine
Plant alkaloids and other natural products
ATC/DDD group L01C.
Vinca alkaloids and analogues
ATC/DDD group L01CA.
Podophyllotoxin derivatives
ATC/DDD group L01CB. Examples include etoposide.
Colchicine derivatives
ATC/DDD group L01CC.
Taxanes
ATC/DDD group L01CD.
Other plant alkaloids and natural products
ATC/DDD group L01CX.
ATC/DDD group L01D.
Actinomycines
ATC/DDD group L01DA.
ATC/DDD group L01DB.
Other cytotoxic antibiotics
ATC/DDD group L01DC.
Other antineoplastic agents
ATC/DDD group L01X.
Platinum compounds
ATC/DDD group L01XA examples include cisplatin, carboplatin, oxaliplatin, and satraplatin.
Methylhydrazines
ATC/DDD group L01XB.
Monoclonal antibodies
ATC/DDD group L01XC. Examples include:
- Anti-EpCAM
- Edrecolomab is monclonal antibody against EpCAM (Entrez protein). Edrecolomab is a "anticolorectal carcinoma antibody for treatment of advanced colorectal carcinoma".[8]
- Anti-ErbB1
- Cetuximab (IMC-C225) is a recombinant, human/mouse chimeric monoclonal antibody that binds to epidermal growth factor receptor (ErbB1, EGFR) and may treat head and neck cancers, colorectal cancer, and non-small cell lung cancer in patients who do not have mutations in the KRAS gene.[9]
- Panitumumab is an "antibody that blocks receptors for epidermal growth factor receptor; approved for advanced colon cancer".[10]
- Anti-ErbB2
- Trastuzumab is a "an antibody against the ErbB-2 receptor that lengthens remission time in metastatic breast cancer."[11]
- Anti-CD3 and anti-EpCAM
- Catumaxomab. Is a monoclonal antibody against CD3 (Entrez protein)and EpCAM (Entrez protein). "Extracorporeal PBMNC coating with catumaxomab may be an option to control intravascular cytokine release induced by therapeutic antibodies".[12]
- Anti-MS4A1 (CD20 antigen)
- Rituximab is a "genetically engineered anti-CD20 (Entrez protein) antibody for the treatment of B-cell lymphoma".[13]
- Anti-SIGLEC3 (CD33)
- Gemtuzumab is an "anti-CD33 (Entrez protein) antibody calicheamicin conjugate".[14]
- Anti-CD52
- Alemtuzumab is a "a therapeutic antibody directed against the CDw52 antigen (Entrez protein) expressed by the lymphocytes and has proven lytic abilities both in vitro and in vivo; has been sequenced".[15]
- Anti-VEGF
- Bevacizumab is an "anti-VEGF (Entrez protein) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary-determining regions from murine VEGF".[16]
Sensitizers used in photodynamic/radiation therapy
ATC/DDD group L01XD.
Protein kinase inhibitors
ATC/DDD group L01XE. Examples include imatinib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib, lapatinib, nilotinib, and temsirolimus.
Other antineoplastic agents
ATC/DDD group L01XX. Examples include hydroxycarbamide (hydroxyurea), tretinoin, and celecoxib.
Dosing
Dosage may be by the area under the curve (AUC), expressed at mg/mL * min.
References
- ↑ Anonymous (2024), Antineoplastic agent (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous. WHO Collaborating Centre for Drug Statistics Methodology. World Health Organization. Retrieved on 2009-02-04.
- ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Antineoplastic Agents, Alkylating (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Methotrexate (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Mercaptopurine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), cytarabine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), edrecolomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. (2009). "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.". N Engl J Med 360 (14): 1408-17. DOI:10.1056/NEJMoa0805019. PMID 19339720. Research Blogging.
- ↑ Anonymous (2024), Panitumumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Trastuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Catumaxomab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Rituximab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Gemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Alemtuzumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Bevacizumab [Substance Name] (English). Medical Subject Headings. U.S. National Library of Medicine.